Dr. Mark Lebwohl
Dermatology (Dermatology Physician)
Medicare and federal program status
Opted out of Medicare from April 1, 2022 through April 1, 2028. Medicare does not pay for this clinician’s services: patients with Medicare sign a private contract and pay the clinician directly. They can still order tests and refer Medicare patients to other providers.
Source: CMS Medicare Opt Out Affidavits (record last updated April 16, 2026). Opting out is a legal choice many clinicians make, often to run a cash or concierge practice.
At a glance
- In the NPI registry since
- 2005
The NPI date is when this clinician registered for a National Provider Identifier, the billing number used on health claims. It is not a license, graduation or board-certification date. NPIs were first issued in May 2005 and became required on claims in 2007–2008, so an early date usually means the clinician was already in practice before then. What an NPI is
Education and training
- 2005Registered with an NPI (national billing number; not a license date) — NPIs began in 2005, so practice likely started earlier
Medicare’s Care Compare data doesn’t list this clinician’s medical school. Undergraduate school, residency, fellowship, licensing exams and board certification aren’t in public federal data. Board certification can be confirmed with the certifying board (ABMS member boards for MDs, AOA boards for DOs).
Specialties and state licenses
-
Dermatology Physician primary
NY license 141913
As reported to the NPI registry. To confirm a license is current, check the state medical board.
Medicare prescriptions
| Drug | Prescriptions |
|---|---|
| Mometasone Furoate Other prescribers in New York, NY | 93 |
| Clobetasol Propionate Other prescribers in New York, NY | 75 |
| Mupirocin Other prescribers in New York, NY | 56 |
| Prednisone Other prescribers in New York, NY | 44 |
| Fluticasone Propionate Other prescribers in New York, NY | 40 |
| Mycophenolate Mofetil Other prescribers in New York, NY | 23 |
| Acitretin | 23 |
| Dupixent Pen (dupilumab) Other prescribers in New York, NY | 22 |
| Siliq (brodalumab) | 21 |
| Tacrolimus Other prescribers in New York, NY | 21 |
Prescriptions filled under Medicare Part D, including refills. CMS leaves out drugs prescribed fewer than 11 times.
Payments from drug and device companies
In 2025, 23 companies reported 181 payments worth $127,834 in total to this clinician.
| Sun Pharmaceutical Industries Inc. | $37,430 |
|---|---|
| Pfizer Inc. | $15,433 |
| Boehringer Ingelheim Pharmaceuticals, Inc. | $13,808 |
| Leo Pharma Inc. | $9,711 |
| Takeda Pharmaceuticals U.S.A., Inc. | $8,812 |
| Eli Lilly and Company | $8,101 |
| Galderma Laboratories, L.P. | $7,183 |
| Janssen Scientific Affairs, LLC | $7,146 |
| Consulting Fee | $89,308 |
|---|---|
| Compensation for services other than consulting (speaking, faculty) | $26,735 |
| Travel and Lodging | $6,807 |
| Food and Beverage | $4,845 |
| Education | $139 |
What the payments were for
| Company | What it was for | Amount |
|---|---|---|
| Pfizer Inc. May 27, 2025 | Consulting Fee LITFULO · IMMUNOLOGY | $9,940 |
| Sun Pharmaceutical Industries Inc. Apr 17, 2025 | Consulting Fee Leqselvi · Dermatology | $8,800 |
| Sun Pharmaceutical Industries Inc. Jun 28, 2025 | Consulting Fee Leqselvi · Dermatology | $8,800 |
| Sun Pharmaceutical Industries Inc. Sep 2, 2025 | Compensation for services other than consulting (speaking, faculty) Leqselvi · Dermatology · in-kind | $7,285 |
| Galderma Laboratories, L.P. Dec 8, 2025 | Compensation for services other than consulting (speaking, faculty) NEMLUVIO · DERMATITIS | $6,800 |
| Janssen Scientific Affairs, LLC Dec 12, 2025 | Consulting Fee | $6,100 |
| E.r. Squibb & Sons, L.l.c. Jan 27, 2025 | Consulting Fee | $4,880 |
| Takeda Pharmaceuticals U.S.A., Inc. Apr 2, 2025 | Consulting Fee | $4,788 |
| Sun Pharmaceutical Industries Inc. Oct 11, 2025 | Consulting Fee Leqselvi · Dermatology | $4,500 |
| Boehringer Ingelheim Pharmaceuticals, Inc. Mar 11, 2025 | Consulting Fee SPEVIGO · IMMUNOLOGY | $3,875 |
All 70 payments other than meals, newest first
| Company | What it was for | Amount |
|---|---|---|
| Pfizer Inc. Dec 26, 2025 | Consulting Fee CIBINQO · Inflammation & Immunology | $3,320 |
| Pfizer Inc. Dec 26, 2025 | Consulting Fee CIBINQO · Inflammation & Immunology | $1,660 |
| Janssen Scientific Affairs, LLC Dec 12, 2025 | Consulting Fee | $6,100 |
| Janssen Scientific Affairs, LLC Dec 12, 2025 | Travel and Lodging travel to HORSHAM, PA · in-kind | $514 |
| Janssen Scientific Affairs, LLC Dec 12, 2025 | Travel and Lodging travel to HORSHAM, PA · in-kind | $503 |
| Galderma Laboratories, L.P. Dec 8, 2025 | Compensation for services other than consulting (speaking, faculty) NEMLUVIO · DERMATITIS | $6,800 |
| Incyte Corporation Dec 4, 2025 | Travel and Lodging Opzelura · Dermatology · travel to New York, NY | $54.30 |
| Incyte Corporation Dec 4, 2025 | Travel and Lodging Opzelura · Dermatology · travel to New York, NY | $27.42 |
| Incyte Corporation Dec 4, 2025 | Travel and Lodging Opzelura · Dermatology · travel to Wilmington, DE | $26.86 |
| Incyte Corporation Dec 3, 2025 | Travel and Lodging Opzelura · Dermatology · travel to Wilmington, DE | $381 |
| Ortho Dermatologics, A Division of Bausch Health US, LLC Dec 1, 2025 | Consulting Fee SILIQ · Dermatology | $2,700 |
| Eli Lilly and Company Nov 25, 2025 | Travel and Lodging TALTZ · Immunology · travel to PARIS, France | $298 |
| Boehringer Ingelheim International GmbH Nov 6, 2025 | Consulting Fee | $1,875 |
| Eli Lilly and Company Oct 31, 2025 | Compensation for services other than consulting (speaking, faculty) TALTZ · Immunology | $3,600 |
| Eli Lilly and Company Oct 31, 2025 | Compensation for services other than consulting (speaking, faculty) TALTZ · Immunology | $3,150 |
| Eli Lilly and Company Oct 30, 2025 | Compensation for services other than consulting (speaking, faculty) TALTZ · Immunology | $900 |
| Takeda Pharmaceuticals U.S.A., Inc. Oct 28, 2025 | Education in-kind | $8.01 |
| Sun Pharmaceutical Industries Inc. Oct 22, 2025 | Consulting Fee Unloxcyt · Oncology | $3,000 |
| Sun Pharmaceutical Industries Inc. Oct 11, 2025 | Consulting Fee Leqselvi · Dermatology | $4,500 |
| Sun Pharmaceutical Industries Inc. Oct 11, 2025 | Travel and Lodging Leqselvi · Dermatology · travel to Dallas, TX · in-kind | $651 |
| Sun Pharmaceutical Industries Inc. Oct 11, 2025 | Travel and Lodging Leqselvi · Dermatology · travel to Dallas, TX · in-kind | $194 |
| Sun Pharmaceutical Industries Inc. Oct 11, 2025 | Travel and Lodging Leqselvi · Dermatology · travel to Dallas, TX | $132 |
| AbbVie Inc. Oct 10, 2025 | Consulting Fee SKYRIZI · IMMUNOLOGY | $650 |
| Boehringer Ingelheim Pharmaceuticals, Inc. Sep 12, 2025 | Compensation for services other than consulting (speaking, faculty) SPEVIGO · IMMUNOLOGY | $2,500 |
| Boehringer Ingelheim Pharmaceuticals, Inc. Sep 12, 2025 | Compensation for services other than consulting (speaking, faculty) SPEVIGO · IMMUNOLOGY | $2,500 |
| Takeda Pharmaceuticals U.S.A., Inc. Sep 4, 2025 | Consulting Fee | $2,394 |
| Sun Pharmaceutical Industries Inc. Sep 2, 2025 | Compensation for services other than consulting (speaking, faculty) Leqselvi · Dermatology · in-kind | $7,285 |
| Regeneron Healthcare Solutions, Inc. Sep 2, 2025 | Education DUPIXENT · IMMUNOLOGY AND INFLAMMATION · in-kind | $94.66 |
| Sun Pharmaceutical Industries Inc. Aug 21, 2025 | Consulting Fee Leqselvi · Dermatology | $1,600 |
| Leo Pharma Inc. Jul 10, 2025 | Consulting Fee ANZUPGO · DERMATOLOGY | $2,715 |
| Sun Pharmaceutical Industries Inc. Jun 28, 2025 | Consulting Fee Leqselvi · Dermatology | $8,800 |
| Sun Pharmaceutical Industries Inc. Jun 28, 2025 | Travel and Lodging Leqselvi · Dermatology · travel to Chicago, IL · in-kind | $319 |
| Sun Pharmaceutical Industries Inc. Jun 28, 2025 | Travel and Lodging Leqselvi · Dermatology · travel to Chicago, IL · in-kind | $281 |
| Sun Pharmaceutical Industries Inc. Jun 28, 2025 | Travel and Lodging Leqselvi · Dermatology · travel to Chicago, IL | $56.28 |
| Eli Lilly and Company Jun 27, 2025 | Travel and Lodging travel to INDIANAPOLIS, NY · in-kind | $135 |
| Boehringer Ingelheim International GmbH Jun 17, 2025 | Consulting Fee | $473 |
| Boehringer Ingelheim International GmbH Jun 17, 2025 | Travel and Lodging travel to Orlando, FL · in-kind | $43.88 |
| Boehringer Ingelheim International GmbH Jun 17, 2025 | Travel and Lodging travel to Orlando, FL · in-kind | $14.86 |
| Pfizer Inc. May 27, 2025 | Consulting Fee LITFULO · IMMUNOLOGY | $9,940 |
| Takeda Pharmaceuticals U.S.A., Inc. May 16, 2025 | Consulting Fee | $466 |
| Janssen Biotech, Inc. May 5, 2025 | Consulting Fee TREMFYA · Immunology | $2,846 |
| Janssen Biotech, Inc. May 5, 2025 | Travel and Lodging TREMFYA · Immunology · travel to ORLANDO, FL | $264 |
| Janssen Biotech, Inc. May 5, 2025 | Travel and Lodging TREMFYA · Immunology · travel to ORLANDO, FL | $55.37 |
| Novartis Pharmaceuticals Corporation May 2, 2025 | Travel and Lodging travel to EAST HANOVER, NJ | $488 |
| Novartis Pharmaceuticals Corporation May 2, 2025 | Travel and Lodging travel to EAST HANOVER, NJ · in-kind | $228 |
| Novartis Pharmaceuticals Corporation May 1, 2025 | Education in-kind | $19.31 |
| Insmed, Inc. Apr 30, 2025 | Education in-kind | $17.38 |
| Amgen Inc. Apr 28, 2025 | Consulting Fee ENBREL · Inflammation | $1,816 |
| Amgen Inc. Apr 28, 2025 | Travel and Lodging ENBREL · Inflammation · travel to ORLANDO, FL | $168 |
| Amgen Inc. Apr 28, 2025 | Travel and Lodging ENBREL · Inflammation · travel to ORLANDO, FL | $35.34 |
| Sun Pharmaceutical Industries Inc. Apr 17, 2025 | Consulting Fee Leqselvi · Dermatology | $8,800 |
| Sun Pharmaceutical Industries Inc. Apr 17, 2025 | Travel and Lodging Leqselvi · Dermatology · travel to Dallas, TX · in-kind | $446 |
| Sun Pharmaceutical Industries Inc. Apr 17, 2025 | Travel and Lodging Leqselvi · Dermatology · travel to Dallas, TX · in-kind | $315 |
| Sun Pharmaceutical Industries Inc. Apr 17, 2025 | Travel and Lodging Leqselvi · Dermatology · travel to Dallas, TX | $121 |
| Janssen Biotech, Inc. Apr 8, 2025 | Travel and Lodging TREMFYA · Immunology · travel to ORLANDO, FL | $33.60 |
| Takeda Pharmaceuticals U.S.A., Inc. Apr 2, 2025 | Consulting Fee | $4,788 |
| Boehringer Ingelheim Pharmaceuticals, Inc. Mar 11, 2025 | Consulting Fee SPEVIGO · IMMUNOLOGY | $3,875 |
| Amgen Inc. Mar 11, 2025 | Travel and Lodging ENBREL · Inflammation · travel to ORLANDO, FL · in-kind | $9.91 |
| Janssen Biotech, Inc. Mar 6, 2025 | Travel and Lodging TREMFYA · Immunology · travel to ORLANDO, FL · in-kind | $70.82 |
| Amgen Inc. Mar 5, 2025 | Travel and Lodging ENBREL · Inflammation · travel to ORLANDO, FL · in-kind | $11.80 |
| Janssen Biotech, Inc. Mar 3, 2025 | Travel and Lodging TREMFYA · Immunology · travel to ORLANDO, FL · in-kind | $18.49 |
| Janssen Biotech, Inc. Mar 3, 2025 | Travel and Lodging TREMFYA · Immunology · travel to ORLANDO, FL · in-kind | $15.52 |
| Leo Pharma Inc. Feb 25, 2025 | Consulting Fee | $3,620 |
| Boehringer Ingelheim Pharmaceuticals, Inc. Feb 11, 2025 | Consulting Fee SPEVIGO · IMMUNOLOGY | $3,100 |
| Boehringer Ingelheim Pharmaceuticals, Inc. Feb 11, 2025 | Travel and Lodging SPEVIGO · IMMUNOLOGY · travel to Ridgefield, CT · in-kind | $123 |
| Takeda Pharmaceuticals U.S.A., Inc. Feb 10, 2025 | Consulting Fee | $1,125 |
| E.r. Squibb & Sons, L.l.c. Jan 27, 2025 | Consulting Fee | $4,880 |
| Leo Pharma Inc. Jan 16, 2025 | Consulting Fee | $2,715 |
| E.r. Squibb & Sons, L.l.c. Jan 8, 2025 | Travel and Lodging travel to Lawrence Township, NJ · in-kind | $770 |
| Boehringer Ingelheim Pharmaceuticals, Inc. Jan 7, 2025 | Consulting Fee SPEVIGO · IMMUNOLOGY | $1,550 |
Each payment as the company reported it, with the products it named. Meals are counted in the totals above but not listed one by one.
From CMS Open Payments. A payment is not evidence of wrongdoing; many are for consulting, teaching or meals. Clinicians can review and dispute their records with CMS.
Industry-funded research
Named as a principal investigator on 6 industry-funded studies in 2025, from 5 companies. The companies reported $486,927 in research payments for these studies, mostly to the institutions running them.
- Ixekizumab Concomitantly Administered With Tirzepatide in Adults With Moderate-to-Severe Plaque Psoriasis and Obesity or Overweight
Eli Lilly and Company · Completed · NCT06588283 - A Phase 3 Multicenter, Randomized, Double-blind, Placebo-controlled and Ustekinumab Active Comparator-controlled Study to Evaluate the Efficacy and Safety of JNJ-77242113 for the Treatment of Participants With Moderat…
Janssen Research & Development, LLC - A Phase 3 Multicenter, Randomized, Double-blind, Placebo-controlled Study to Evaluate the Efficacy and Safety of JNJ-77242113 for the Treatment of Participants with Moderate to Severe Plaque Psoriasis with Randomized …
Janssen Research & Development, LLC - Study of Subcutaneous (Injected Under the Skin) Risankizumab to Assess Change in Disease Symptoms in Adult Participants With Moderate to Severe Plaque Psoriasis With Palmoplantar Involvement
AbbVie Inc. · Completed · NCT04713592 - A multi-centre, randomised, placebo-controlled, double-blind, parallel-group trial to evaluate safety and efficacy of spesolimab (BI 655130) in adult patients with ulcerative pyoderma gangrenosum (PG) who require syst…
Boehringer Ingelheim International GmbH - Efficacy and Safety of Subcutaneous Dupilumab for the Treatment of Adult Participants With Chronic Pruritus of Unknown Origin (CPUO) (LIBERTY-CPUO-CHIC)
Sanofi US Services Inc. · Recruiting · NCT05263206
From CMS Open Payments research payments, where companies name up to five principal investigators per payment. Research payments usually go to hospitals, universities and research sites, not to the investigator personally. A payment is not evidence of wrongdoing.